Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2026 was $6,973 Mil.
During the past 12 months, Ono Pharmaceutical Co's average Total Assets Growth Rate was 1.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 13 years, Ono Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 12.70%. The lowest was -7.80%. And the median was 5.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Ono Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Ono Pharmaceutical Co Total Assets Related Terms
Ono Pharmaceutical Co Total Assets Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Ono Pharmaceutical Co's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co (OPHLF) has a Total Assets of $6,973 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Ono Pharmaceutical Co and its competitors.
Is Ono Pharmaceutical Co's Total Assets too high?
Ono Pharmaceutical Co's current Total Assets is $6,973 Mil. Overall, Ono Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Total Assets compare to LLY and JNJ?
Ono Pharmaceutical Co's Total Assets of $6,973 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current Total Assets is $6,973 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (OPHLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.88, compared to a current price of $14.90 — trading 15.7% above its estimated fair value. The current Total Assets is $6,973 Mil. Ono Pharmaceutical Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Ono Pharmaceutical Co (OPHLF), the current Total Assets is $6,973 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (OPHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of $14.90 is trading 15.7% above its estimated GF Value™ of $12.88.
GuruFocus considers Ono Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for OPHLF:
Total Assets: $6,973 Mil
GF Value™: $12.88 vs. price of $14.90 (15.7% above fair value)
No single metric tells the full story. See the OPHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
74GF Score
Get the complete analysis for OPHLF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPHLF has been successfully added to your 
